Navigation Links
Hanmi Pharmaceuticals to Acquire the Rights for a Promising Phase II Anti-cancer Src Kinase/Pretubulin Dual Inhibitor from Kinex Pharmaceuticals, in Selected Asian Territories
Date:4/20/2011

Dr. Rudolf Kwan, who was previously Vice-President of Clinical Research, Schering-Plough Research Institute.

About Kinex Pharmaceuticals, LLC

Kinex Pharmaceuticals, headquartered in Buffalo, New York, USA, is using its proprietary technologies Mimetica™ and Opal™ to discover and develop novel drugs for oncology and immuno-modulatory diseases. More information of Kinex Pharmaceuticals can be found at  www.kinexpharma.com

Kinex Pharmaceuticals, LLC – Caution Regarding Forward-looking Information

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Kinex Pharmaceuticals cautions investors that any forward-looking statements or projections made by Kinex Pharmaceuticals, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected.

About Hanmi Pharmaceutical, Co., Ltd

Hanmi Pharmaceutical, Co., Ltd., headquartered in Seoul, South Korea, is one of the leading pharmaceutical companies in Korea. Hanmi Pharmaceuticals has more than 200 products that have been developed for the treatment of a broad range of important human diseases. For further information about Hanmi Pharmaceuticals, please refer to www.hanmipharm.com.

Hanmi Pharmaceuticals Forward-looking Statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 or Korean Securities and Exchange Law, Hanmi Pharmaceuticals cautions investors that any forward-looking statements or projections made by Hanmi Pharmaceuticals, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected.

Kinex Pharmaceuticals Inquiries:
Lyn M. Dyster, Ph.D.
VP, Opera
'/>"/>

SOURCE Kinex Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
2. Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 36th Annual Health Care Conference
4. Sagent Pharmaceuticals Upsizes and Prices Initial Public Offering
5. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
6. Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection
7. Bexion Pharmaceuticals Receives Outstanding Biotech Innovation Award
8. Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient
9. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
10. Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl
11. Amylin Pharmaceuticals Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014   Hospira, Inc. ... provider of injectable drugs and infusion technologies, today announced ... 33rd Annual Healthcare Conference on Wednesday, Jan. 14, 2015, ... is scheduled to begin at 10:30 a.m. Pacific time ... to all interested parties through a live audiocast accessible ...
(Date:12/19/2014)... Colo. , Dec. 19, 2014  Monarch America ... Cannabis Kinetics Corp.) is pleased to provide this review ... continued growth in 2015. "Over this past ... goals and I am extremely proud to say that ... position today than it has ever been," stated ...
(Date:12/19/2014)... -- Somewhere between dropping five pounds and cooking more ... Audicus , a next-generation hearing aids company, will help ... Hearing loss is the third most common chronic ... often unaddressed. Forty-eight million Americans have hearing loss, but ... due to price. Hearing aids traditionally cost $7,000 per ...
Breaking Medicine Technology:Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Audicus Will Help People Resolve to Hear Better in 2015 2
... 2010 Stereotaxis, Inc. (Nasdaq: STXS ) announced ... to offer its common stock in a registered public offering ... Act of 1933. Stereotaxis also intends to grant the underwriters ... common stock to cover over-allotments, if any. Stereotaxis ...
... 10, 2010 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ... Capital Markets 7th Annual Healthcare Conference on Wednesday, November 17, ...   Interested parties may access a live webcast ... It is recommended that listeners log on 15 ...
Cached Medicine Technology:Stereotaxis Announces Public Offering of Common Stock 2Stereotaxis Announces Public Offering of Common Stock 3Stereotaxis Announces Public Offering of Common Stock 4Onyx Pharmaceuticals to Present at the Lazard Capital Markets 7th Annual Healthcare Conference 2
(Date:12/21/2014)... 2014 Hundreds of Byetta lawsuits ... involving a class of Type 2 diabetes drugs ... in a federal multidistrict litigation now underway in ... Liebhard LLP reports. According to an Order dated ... cut-off date of February 27, 2014 for discovery ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 Serious Buyer, ... for Vintage 1967 Jm Morrison and the Doors International Ballroom ... This would also be the only time that Morrison's ... was on Nov. 25, 1967. According to Hawley, “This ... They did play the Alexandria Roller Rink earlier that ...
(Date:12/21/2014)... As testosterone therapy lawsuit filings ... and blood clots from using testosterone products such as ... shows that the male hormone testosterone may increase the ... published in the Proceedings of the National Academy of ... group of male rats with naturally occurring colon cancer. ...
(Date:12/20/2014)... BambooIndustry.com is a leading eco-friendly bamboo flooring ... bamboo flooring promotion for the coming 2015. , ... and offers the best bamboo products and services ... all customers can enjoy a special discount, up ... BambooIndustry.com from press releases. , The bamboo flooring ...
(Date:12/20/2014)... December 20, 2014 DePuy Pinnacle ... metal-on-metal version of the artificial hip system was ... and federal courts, Bernstein Liebhard LLP reports. According ... County Superior Court on December 2nd, counsel in ... deposition of plaintiffs on November 19, 2014, with ...
Breaking Medicine News(10 mins):Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4
... California, San Diego (UCSD) School of Medicine, liver cancer ... death and renewal – liver cell proliferation. ... in advance of publication in the journal Proceedings of ... JNK1-mediated cell death and compensatory proliferation. The findings by ...
... reported that there appears to be three variations of ... on humans upon their susceptibility towards tuberculosis// . Researchers ... to why some patients infected with the Mycobacterium tuberculosis ... not affected. The findings was published in the online ...
... that has twice the amount of oleic acid found in ... //is being tested by researchers at the Iowa State University ... oil can go where no unhydrogenated soybean oil has gone ... sauces and non-dairy creamers) that require more stability than previous ...
... Reddy's Laboratories today announced that it has launched the authorized ... June 19. // ,The company has also launched ... mg, 10 mg, 20 mg, 40 mg and 80 mg ... year, the company entered into separate agreements with Merck that ...
... habits can help lessen the intensity of migraines, says ... neurology //at the University of North Carolina Medical School, ... who improved their sleep habits had reduced headache frequencies. ... headache frequency by 29 percent and headache intensity by ...
... fund raisers are taking part in the moon walk which will ... walk along with the famous TV star Lorraine Kelly. ... one million pounds for breast cancer and the Maggie’s Centre. They ... the day of the event. ,Hence the name Moon ...
Cached Medicine News:Health News:Repeated Liver Cell Proliferation, a Cause for Liver Cancer 2Health News:Susceptibility Of TB In Humans Might Be Due To Three Human Gene Variants 2Health News:New Variety Of Soybean Oil 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: